The underlying inflammatory chronic disease influences infliximab pharmacokinetics

Infliximab is an anti-tumor necrosis factor monoclonal antibody approved in chronic inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn's disease (CD) and ulcerative colitis (UC). Infliximab pharmacokinetics is variable between...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:MAbs
Main Authors: Passot, Christophe, Mulleman, Denis, Bejan-Angoulvant, Theodora, Aubourg, Alexandre, Willot, Stephanie, Lecomte, Thierry, Picon, Laurence, Goupille, Philippe, Paintaud, Gilles, Ternant, David
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2016
Assuntos:
Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5058621/
https://ncbi.nlm.nih.gov/pubmed/27589009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2016.1216741
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados